PMA approvals moved off the Federal Register

FDA Radar’s own item taxonomy carries a category called PMA Approval — a label built to sit next to 510(k) Clearance and De Novo Grant on the dashboard. No item has ever carried it, and none will, for a reason that has nothing to do with this pipeline’s reach: in January 2022, FDA stopped putting PMA approvals in the Federal Register at all.

What the category was built to read

FDA Radar’s Federal Register adapter is the source for five of the twelve categories in its own taxonomy — FDA Guidance, Final Rule, Proposed Rule, Classification Change, and the catch-all Federal Register Notice — each one keyed off the actual document type and title text the Federal Register publishes. Three other categories in the same file — Safety Communication, De Novo Grant, Standards Recognition — have never been assigned by any source either, each empty for its own reason. PMA Approval sits with them, styled the same way, built on the same assumption every populated category shares: that somewhere in the Federal Register is a document announcing it. That assumption used to be true.

The rule that emptied it

Through 2021, FDA published a running quarterly notice in the Federal Register listing every PMA and Humanitarian Device Exemption approval and denial issued that quarter — the paper trail a Federal Register-based feed could have followed. A final rule effective January 13, 2022 discontinued that practice entirely. FDA’s own stated reason was to stop duplicating itself: approvals and denials would still be announced, just on FDA’s own PMA database page instead of in the Federal Register, alongside the summaries of safety and effectiveness data the agency was already posting there. The device didn’t change. The channel did — and a source built to read the Federal Register lost the one document type it needed for this category, four years before this pipeline was written.

A category in a taxonomy file is a promise about where a fact will show up. FDA moved the fact and left the promise standing.

Not a gap this pipeline can close by watching harder

This isn’t the product-code annotation openFDA leaves empty on a recall, or a document that exists somewhere and simply isn’t machine-readable yet. It is a document type FDA deliberately stopped producing, by its own rule, in its own words, for its own operational reasons. A Federal Register watch built to be more thorough would still find nothing, because the 2022 rule didn’t change how thoroughly the Federal Register gets read — it changed what FDA puts there at all.

The practice

A PMA approval or denial that matters to a portfolio — a competitor’s device, a predicate’s Class III cousin, a device in the same review panel — has to be read directly from FDA’s own PMA database, on a cadence, the way this record now actually gets published, rather than searched for in the Federal Register archive where it used to live and no longer does. Whether a specific approval changes anything about a specific submission strategy is a determination for a regulatory professional reading that record, not a category any monitoring tool can supply. This is regulatory intelligence about where the record moved, never regulatory advice about what a competitor’s approval means for yours.